Suppression amblyopia

Summary

Suppression amblyopia (MONDO:0001019) is a disease and 9 clinical trials. Top therapeutic interventions include valproic acid. A subtype of amblyopia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	suppression amblyopia
Mondo ID	MONDO:0001019
DOID	DOID:10375
ICD-10-CM	H53.03
SNOMED CT	35600002
UMLS	C0750903
MedGen	152911
Is cancer (heuristic)	no

Also known as: strabismic amblyopia

Disease family

This is a subtype of amblyopia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › perceptual disorders › vision disorder › amblyopia › suppression amblyopia

Related subtypes (2): ametropic amblyopia, disuse amblyopia

Subtypes (1): toxic amblyopia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07226141	PHASE1/PHASE2	NOT_YET_RECRUITING	Valproate for the Treatment of Residual Amblyopia
NCT05620173	Not specified	ACTIVE_NOT_RECRUITING	Validation of New Virtual Reality Treatment for Children With Lazy Eye Using the Vedea Amblyopia Therapy (VAT)
NCT07547670	Not specified	NOT_YET_RECRUITING	Effectiveness of tDCS in Paediatric Amblyopia.
NCT07563946	Not specified	NOT_YET_RECRUITING	3D Movie Viewing vs Occlusion for Treating Amblyopia in Children
NCT02555384	Not specified	WITHDRAWN	AMblyopia Treatment Through PErceptual Training in Children (AMPEL)
NCT04195711	Not specified	COMPLETED	Comparative Validation of Blinq and 2WIN Vision Screeners
NCT04313257	Not specified	COMPLETED	Monocular Action Video Game Treatment of Amblyopia
NCT04315649	Not specified	COMPLETED	Effect of 3D Movie Viewing on Stereopsis in Strabismus and / or Anisometropic Amblyops
NCT04429659	Not specified	COMPLETED	Changes in Refractive Error in Patients With Both Partially Refractive Esotropia and Amblyopia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
VALPROIC ACID	4	2